Drug Profile

CTX 320

Alternative Names: CTX-320

Latest Information Update: 10 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CRISPR Therapeutics
Class Cardiovascular therapies; Gene therapies
Mechanism of Action Gene transference; Lipoprotein A expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Cardiovascular disorders

Most Recent Events

08 Jan 2024 Phase-I clinical trials in Cardiovascular disorders in Switzerland (Parenteral), prior to January 2024
11 Nov 2023 Pharmacodynamics data from a preclinical trial in Cardiovascular disorders presented at the American Heart Association Scientific Sessions (AHA-2023)
06 Nov 2023 CRISPR Therapeutics plans a clinical trial for Cardiovascular disorders (Parenteral), in the first half of 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com